Financial Advocates Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-3,767
Closed -$306K 788
2025
Q1
$306K Buy
3,767
+68
+2% +$6.08K 0.02% 559
2024
Q4
$333K Sell
3,699
-8,269
-69% -$801K 0.02% 571
2024
Q3
$1.3M Buy
+11,968
New +$1.18M 0.07% 251
2024
Q2
Sell
-6,413
Closed -$605K 835
2024
Q1
$605K Buy
6,413
+798
+14% +$74K 0.04% 421
2023
Q4
$534K Buy
5,615
+2,440
+77% +$181K 0.03% 417
2023
Q3
$364K Buy
+3,175
New +$254K 0.03% 482
2023
Q1
Sell
-5,876
Closed -$488K 829
2022
Q4
$488K Sell
5,876
-3,580
-38% -$290K 0.04% 454
2022
Q3
$585K Buy
9,456
+1,827
+24% +$154K 0.05% 375
2022
Q2
$567K Buy
7,629
+1,148
+18% +$86.2K 0.05% 377
2022
Q1
$582K Buy
+6,481
New +$598K 0.04% 409
2021
Q2
Sell
-3,284
Closed -$432K 847
2021
Q1
$453K Sell
3,284
-1,201
-27% -$180K 0.03% 504
2020
Q4
$368K Buy
+4,485
New +$574K 0.03% 517

Other funds holding XBI

Financial Advocates Investment Management's XBI Position: Q2 2025 in Review

Financial Advocates Investment Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 3,767 shares — an estimated $306K sold.

Financial Advocates Investment Management first reported a position in XBI in Q4 2020 and held it in 12 quarters. The position peaked at $1.3M in Q3 2024. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.

  • Financial Advocates Investment Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
  • Financial Advocates Investment Management sold 3,767 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $306K.
  • Financial Advocates Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 12 quarters.
  • Financial Advocates Investment Management's State Street SPDR S&P Biotech ETF position peaked at $1.3M in Q3 2024.
  • 625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.

Based on Financial Advocates Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.